Claire Lancaster, Ivan Koychev, Jasmine Blane, Amy Chinner, Christopher, Chatham, Kirsten Taylor, Chris Hinds
Journal of Clinical and Experimental Neuropsychology. 2019
DOI: https://doi.org/10.1080/13803395.2020.1714551
Claire Lancaster, Ivan Koychev, Jasmine Blane, Amy Chinner, Christopher, Chatham, Kirsten Taylor, Chris Hinds
Journal of Clinical and Experimental Neuropsychology. 2019
DOI: https://doi.org/10.1080/13803395.2020.1714551
Maria-Eleni Dounavi, Elijah Mak, Katie Wells, Karen Ritchie, Craig W. Ritchie, Li Su, John T.O’ Brien
Neurobiology of Ageing. 2020
DOI: https://doi.org/10.1016/j.neurobiolaging.2020.03.006
Summary
In this study, we found that participants with an APOEe4 genotype (a known genetic risk factor for dementia) were more likely to have a smaller hippocampal molecular layer, and this change was apparent at both the baseline and 2-year follow up.
Together with previous findings, it appears that the molecular layer may be one of the first areas to show vulnerability to the pathological hallmarks of Alzheimer’s. However, it was noted that differences in the molecular layer were not significantly related to dementia risk defined by family history or cardiovascular factors.
In 2019 the PREVENT Dementia Programme held it’s first General Assembly. Hosted by Trinity College Dublin, this meeting provided an opportunity for researchers from across the PREVENT network to gather and exchange ideas on the many different plans for analysis of all areas of the cohort data. Here we meet a number of our PREVENT researchers, discover their roles within the programme and ask how they found the inaugural PREVENT General Assembly.